Welcome to
CAR T-cell Therapy as a Treatment for Blood Cancer Patients
Friday, January 19, 2018
DoubleTree by Hilton Hotel Philadelphia Center City
237 S Broad St, Philadelphia, PA, 19107
Breakfast: 8:00 am
Program: 8:30 am - 2:00 pm
TARGET AUDIENCE
This activity has been designed to meet the educational needs of hematologists/oncologists, fellows, medical oncologists, physician assistants, nurse practitioners, nurses, social workers at intermediate and advanced level and other HCPs involved in the treatment of patients with blood cancer.
LEARNING OBJECTIVES
At the conclusion of this program, participants will be able to:
• Describe the latest developments in immunotherapy for patients with relapsed/refractory blood cancer
• Identify the emerging role of CAR T-cell treatment options
• Discuss treatment plans for patient care
• Address potential short and long term effects & side effects management
• Identify patients who could potentially enroll in CAR T trials
• Engage patients and caregivers in discussions on clinical trials for CAR T, including benefits, risks and barriers to entry
This activity is supported by The Leukemia & Lymphoma Society with educational grants from Kite Pharma and Juno Therapeutics
